Why the study?
Do patients with apical hypertrophic cardiomyopathy have different clinical features and outcomes compared to those with asymmetric septal hypertrophy?
Do patients with apical hypertrophic cardiomyopathy have different clinical features and outcomes compared to those with asymmetric septal hypertrophy?
Apical hypertrophic cardiomyopathy comprises a significant proportion of HCMP in Korea and is associated with an older age of presentation, higher prevalence of hypertension, and fewer cardiac events compared to asymmetric septal hypertrophy.
BACKGROUND: We sought to test whether patients with apical hypertrophic cardiomyopathy (APH) have different clinical features compared to those with typical asymmetric septal hypertrophy (ASH). METHODS: Among 32,534 patients who underwent routine echocardiography at Asan Medical Center from January 2000 to December 2001, 305 patients (0.9%), who were finally diagnosed with hypertrophic cardiomyopathy (HCMP), were evaluated. The type of HCMP was classified according to the echocardiographic findings. RESULTS: ASH was the most frequent type (n=160, 53%, group I), and APH was the second most frequent (n=91, 30%, group II). Mean age (60.8 +/- 10 vs. 48.2 +/- 14 years, p<0.001) and prevalence of hypertension (32% vs. 19%, p=0.022) were significantly higher in group II than in group I. Family history of HCMP (4.4% vs. 0% p=0.043) and sudden cardiac death (8.8% vs. 1.1% p=0.014) was more prevalent in group I. During the follow-up period of 32.0 +/- 37.2 months, cardiac events occurred at a significantly higher rate in group I (25.5% vs. 8.8%, p=0.003). CONCLUSION: APH comprises a significant proportion of HCMP in Korea and patients with APH show different clinical features compared to those with ASH.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: